<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01937351</url>
  </required_header>
  <id_info>
    <org_study_id>P0555</org_study_id>
    <nct_id>NCT01937351</nct_id>
  </id_info>
  <brief_title>Evaluation of the Pantheris Atherectomy System</brief_title>
  <acronym>VISION</acronym>
  <official_title>Evaluation of the Pantheris Optical Coherence Tomography Imaging Atherectomy System for Use in the Peripheral Vasculature</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avinger, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avinger, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      A non-randomized, prospective, global clinical trial of the Avinger Pantheris System, an
      atherectomy device that provides directional visualization and imaging as an adjunct to
      fluoroscopy to aid removal of plaque in diseased lower extremity arteries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial will enroll up to 173 subjects diagnosed with peripheral arterial disease of the
      lower extremities at up to 20 sites (up to 3 international sites), including 133 Intention to
      Treat subjects and up to 2 additional Roll-In subjects at each site (up to 40 Roll-In
      subjects total). The primary disease must be located in reference vessel diameters ≥ 2.5 mm
      and ≤ 7.0 mm. Trial success is focused on safety including rates of major adverse events
      through 6 months as adjudicated by a Clinical Events Committee. Effectiveness will be
      evaluated using technical success, defined as the percent of target lesions that have a
      residual diameter stenosis &lt;50% post-treatment with the Pantheris device alone as assessed by
      Angiographic Core Lab.

      The study has been extended to collect prospective follow-up data at 24-months (+/- 60 days)
      to look at long-term outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety Endpoint</measure>
    <time_frame>Day 0 through 6 Months</time_frame>
    <description>The primary safety endpoint is defined as freedom from a composite of major adverse events (MAE) through 6-Month follow-up as adjudicated by an independent Clinical Events Committee (CEC). Individual MAEs include:
Cardiovascular related death
Unplanned, major index limb amputation
Clinically driven target lesion revascularization (TLR)
Myocardial infarction
Device related events:
Clinically significant perforation
Clinically significant dissection
Clinically significant embolus
Pseudoaneurysm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Effectiveness Endpoint</measure>
    <time_frame>Day 0</time_frame>
    <description>The primary efficacy endpoint of technical success is defined as the percent of target lesions that have a residual diameter stenosis &lt;50% post the Pantheris device alone, as assessed by an independent Angiographic Core Laboratory.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety Endpoint</measure>
    <time_frame>Day 0 through Day 30</time_frame>
    <description>Freedom from MAEs as defined above, through 30 days (or hospital discharge, whichever is longer) as adjudicated by an independent CEC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety Endpoint</measure>
    <time_frame>Day 0</time_frame>
    <description>Freedom from procedural emboli, defined as a change in any visualized runoff vessel (other than vasospasm and dissection) at any time during the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety Endpoint</measure>
    <time_frame>Day 0 through 6 Months</time_frame>
    <description>Freedom from clinically driven Target Vessel Revascularization (TVR) through 6 months, as adjudicated by an independent CEC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Effectiveness Endpoint</measure>
    <time_frame>Day 0</time_frame>
    <description>Procedural success defined as the percent of target lesions that have residual diameter stenosis &lt; 30% post-Pantheris and any other adjunctive therapy, determined by independent Angiographic Core Laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Effectiveness Endpoint</measure>
    <time_frame>Day 30 and 6 Months</time_frame>
    <description>Ankle-Brachial Index at 30 days and 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Effectiveness Endpoint</measure>
    <time_frame>Day 0, Day 30 and 6 Months</time_frame>
    <description>Rutherford Classification at 30 days and 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Effectiveness Endpoint</measure>
    <time_frame>Day 0, Day 60 and 6 Months</time_frame>
    <description>Changes in Quality of Life measures from Baseline at 30 days and 6 months using Short Form (SF)-12 &amp; Vascular Quality of Life (VascuQoL).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Pantheris Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Atherectomy using the Pantheris system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pantheris System</intervention_name>
    <arm_group_label>Pantheris Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old;

          -  Subject is a candidate for percutaneous intervention for peripheral arterial disease
             in the legs;

          -  Subject is willing and able to give informed consent;

          -  Documented symptomatic atherosclerotic peripheral arterial disease Rutherford
             Classification 2-5;

          -  Reference vessel lumen proximal to target lesion ≥ 2.5 mm and ≤ 7.0 mm in diameter by
             visual estimation;

          -  Subject has de novo target lesion(s) with stenosis &gt;70% by visual estimation distal to
             the profunda femoral artery. No more than 2 lesions may be treated with the Pantheris
             device;

          -  Target lesion length ≤ 15 cm (may be two tandem lesions that do not exceed 15cm in
             total length);

          -  Subject is capable of meeting requirements and be present at the follow-up clinic
             visits at 30 days and 6 months;

          -  At least one patent tibial run-off vessel at baseline.

        Inclusion Criteria for the 24-month follow up:

          -  Completed the 6-month follow-up visit

          -  Re-consented prior to the 24-month follow-up visit

        Exclusion Criteria:

          -  Subject is pregnant or breast feeding;

          -  Rutherford Class 0 to 1 (asymptomatic and mild claudication);

          -  Rutherford Class 6 (critical limb ischemia);

          -  Moderate to severe calcification of the target lesion;

          -  Acute ischemia and/or acute thrombosis of the Superficial Femoral Artery
             (SFA)-Popliteal segment;

          -  In-stent restenosis within the target lesion;

          -  Target lesion with any type of stent or graft;

          -  Target lesion in the iliac artery;

          -  Target lesion stenosis &lt;70%;

          -  Subjects with significant (≥70%) occlusive lesions proximal to the target lesion not
             successfully treated during the index procedure (upstream disease) and prior to
             treatment of the target lesion;

          -  Endovascular or surgical procedure performed on the index limb less than or equal to
             30 days prior to the index procedure;

          -  Planned endovascular or surgical procedure 30 days after the index procedure;

          -  Lesion in the contralateral limb requiring intervention during the index procedure or
             within 30 days of the index procedure;

          -  Subjects with active systemic infections whether they are being currently treated or
             not;

          -  Subjects on chronic hemodialysis or creatinine level &gt;2.0mg/dL;

          -  Evidence or history of intracranial or gastrointestinal bleeding, intracranial
             aneurysm, myocardial infarction or stroke within the past 2 months;

          -  Evidence or history of aneurysmal target vessel within the past 2 months;

          -  History of severe trauma, fracture, major surgery or biopsy of a parenchymal organ
             within the past 14 days;

          -  Known allergy to contrast agents or medications used to perform endovascular
             intervention that cannot be adequately pre-treated;

          -  Subjects in whom anti-platelet, anticoagulant, or thrombolytic therapy is
             contraindicated;

          -  History of heparin-induced thrombocytopenia (HIT);

          -  Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet
             count less than 100,000/mm2, known coagulopathy, or International Normalized Ratio
             (INR) &gt;1.5;

          -  Any thrombolytic therapy within 2 weeks of the index procedure;

          -  Any clinical and/or angiographic complication attributed to the use of another device
             prior to the insertion of the study device into the subject;

          -  Subjects or their legal guardians who have not or will not sign the Informed Consent;

          -  Subjects who are unwilling or unable to comply with the follow-up study requirements;

          -  Participation in any study of an investigational device, medication, biologic or other
             agent within 30 days prior to enrollment that is either a cardiovascular study or
             could, in the judgment of the investigator, affect the results of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gray Bennett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jackson Heart Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Billy Crowder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jackson Heart Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arne Schwindt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Muenster Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Bernard's Medical Center</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Heart Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center/Cardiovascular Research Foundation of Southern California</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medstar Washington Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Vascular and Interventional</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Medical Center, Cardiovascular Associates</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Christ Hospital and Medical Center</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John Hospital and Medical Center</name>
      <address>
        <city>Detoit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Detroit Medical Center Cardiovascular Institute Harper-Hutzel Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Dominic Hospital</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deborah Heart and Lung Center</name>
      <address>
        <city>Browns Mills</city>
        <state>New Jersey</state>
        <zip>08015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Peters University Hospital</name>
      <address>
        <city>New Brunswi</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hatton Institute for Research and Education, Good Samaritan Hospital - Bethesda North</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayton Heart Center/Good Samaritan Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jobst Vascular Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Einstein Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Heart</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Muenster Hospital</name>
      <address>
        <city>Muenster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2013</study_first_submitted>
  <study_first_submitted_qc>September 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2013</study_first_posted>
  <results_first_submitted>April 5, 2017</results_first_submitted>
  <results_first_submitted_qc>April 5, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 12, 2017</results_first_posted>
  <last_update_submitted>April 5, 2017</last_update_submitted>
  <last_update_submitted_qc>April 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atherectomy</keyword>
  <keyword>Optical Coherence Tomography</keyword>
  <keyword>Lumivascular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Primary Cohort</title>
          <description>Atherectomy with Pantheris System</description>
        </group>
        <group group_id="P2">
          <title>Roll-in Group</title>
          <description>Atherectomy with Pantheris System</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated w Study Device</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>30-Day Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>6-Month Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated w device, per protocol fail</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The study consisted of Roll-In Cohort and a Primary Analysis Cohort. Up to 2 Roll-In subjects could be treated at each study site prior to initiation of enrollment in the Primary Analysis Cohort.Roll-In subjects were designed to provide the Investigator an opportunity to gain experience with the Pantheris System for learning curve purposes.</population>
      <group_list>
        <group group_id="B1">
          <title>Primary Cohort</title>
          <description>The Primary Cohort consisted of either the 1st subject enrolled after the Roll-In cohort or the 1st subject enrolled if the site did not utilize Roll-In subjects.
The Primary Cohort was analyzed as two separate sub-cohorts: Intention to Treat and Per Protocol. The Intention to Treat Cohort includes all subjects that were enrolled. The Per Protocol Cohort includes subjects who were enrolled, and had the Pantheris Catheter or Occlusion Sheath device inserted into the vasculature. To be included in this cohort, the Pantheris Catheter also had to be successfully advanced to the intended target lesion. This cohort is a subset of subjects enrolled into the Intention to Treat Cohort.
The Primary Per Protocol Cohort was the cohort used to determine if the primary endpoints of the VISION Study were met.</description>
        </group>
        <group group_id="B2">
          <title>Roll-In Cohort</title>
          <description>The Roll-In Cohort consists of either the 1st subject or 1st and 2nd subjects treated at each site prior to enrollment of subjects into the Primary Cohort. Roll-Ins were designed to provide the Investigator an opportunity to gain experience with the Pantheris System (Catheter and Optical Coherence Tomography-assisted orientation) for learning curve purposes. Certain sites were exempt from enrolling in the Roll-In Cohort.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="134"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="162"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Subject age in years</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.4" spread="10.5"/>
                    <measurement group_id="B2" value="66.7" spread="10.5"/>
                    <measurement group_id="B3" value="67.3" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Unavailable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="179.5" spread="43.0"/>
                    <measurement group_id="B2" value="199.3" spread="45.3"/>
                    <measurement group_id="B3" value="182.9" spread="44.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>inches</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.8" spread="3.8"/>
                    <measurement group_id="B2" value="66.5" spread="4.1"/>
                    <measurement group_id="B3" value="66.7" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Safety Endpoint</title>
        <description>The primary safety endpoint is defined as freedom from a composite of major adverse events (MAE) through 6-Month follow-up as adjudicated by an independent Clinical Events Committee (CEC). Individual MAEs include:
Cardiovascular related death
Unplanned, major index limb amputation
Clinically driven target lesion revascularization (TLR)
Myocardial infarction
Device related events:
Clinically significant perforation
Clinically significant dissection
Clinically significant embolus
Pseudoaneurysm</description>
        <time_frame>Day 0 through 6 Months</time_frame>
        <population>All per-protocol subjects who completed the 6-month follow-up were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Per Protocol Cohort</title>
            <description>Atherectomy with Pantheris System</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Safety Endpoint</title>
          <description>The primary safety endpoint is defined as freedom from a composite of major adverse events (MAE) through 6-Month follow-up as adjudicated by an independent Clinical Events Committee (CEC). Individual MAEs include:
Cardiovascular related death
Unplanned, major index limb amputation
Clinically driven target lesion revascularization (TLR)
Myocardial infarction
Device related events:
Clinically significant perforation
Clinically significant dissection
Clinically significant embolus
Pseudoaneurysm</description>
          <population>All per-protocol subjects who completed the 6-month follow-up were included in the analysis</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Effectiveness Endpoint</title>
        <description>The primary efficacy endpoint of technical success is defined as the percent of target lesions that have a residual diameter stenosis &lt;50% post the Pantheris device alone, as assessed by an independent Angiographic Core Laboratory.</description>
        <time_frame>Day 0</time_frame>
        <population>Analysis was performed on per protocol cohort, and results were calculated based on number of lesions that were treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Per Protocol Cohort</title>
            <description>Atherectomy with Pantheris System</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Effectiveness Endpoint</title>
          <description>The primary efficacy endpoint of technical success is defined as the percent of target lesions that have a residual diameter stenosis &lt;50% post the Pantheris device alone, as assessed by an independent Angiographic Core Laboratory.</description>
          <population>Analysis was performed on per protocol cohort, and results were calculated based on number of lesions that were treated.</population>
          <units>percentage of lesions</units>
          <param>Number</param>
          <units_analyzed>lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Safety Endpoint</title>
        <description>Freedom from MAEs as defined above, through 30 days (or hospital discharge, whichever is longer) as adjudicated by an independent CEC.</description>
        <time_frame>Day 0 through Day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Per Protocol Cohort</title>
            <description>Atherectomy with Pantheris System</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Safety Endpoint</title>
          <description>Freedom from MAEs as defined above, through 30 days (or hospital discharge, whichever is longer) as adjudicated by an independent CEC.</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Safety Endpoint</title>
        <description>Freedom from procedural emboli, defined as a change in any visualized runoff vessel (other than vasospasm and dissection) at any time during the procedure.</description>
        <time_frame>Day 0</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Safety Endpoint</title>
        <description>Freedom from clinically driven Target Vessel Revascularization (TVR) through 6 months, as adjudicated by an independent CEC.</description>
        <time_frame>Day 0 through 6 Months</time_frame>
        <posting_date>04/2017</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Effectiveness Endpoint</title>
        <description>Procedural success defined as the percent of target lesions that have residual diameter stenosis &lt; 30% post-Pantheris and any other adjunctive therapy, determined by independent Angiographic Core Laboratory.</description>
        <time_frame>Day 0</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Effectiveness Endpoint</title>
        <description>Ankle-Brachial Index at 30 days and 6 months.</description>
        <time_frame>Day 30 and 6 Months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Effectiveness Endpoint</title>
        <description>Rutherford Classification at 30 days and 6 months.</description>
        <time_frame>Day 0, Day 30 and 6 Months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Effectiveness Endpoint</title>
        <description>Changes in Quality of Life measures from Baseline at 30 days and 6 months using Short Form (SF)-12 &amp; Vascular Quality of Life (VascuQoL).</description>
        <time_frame>Day 0, Day 60 and 6 Months</time_frame>
        <posting_date>04/2017</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All subjects between enrollment and 6 month follow-up.</time_frame>
      <desc>There were three types of events in the study. Major Adverse Event (MAE), Serious Adverse Event (SAE), Adverse Event (AE).
Collection of event data was reported by the site within 24 hours for MAEs, 10 days for SAEs and collected during routine monitoring visits for all other AEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>Primary Cohort</title>
          <description>Pantheris System</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute on Chronic Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Mild Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Right Anterior Tibia Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Hypotension, sustained</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Acute on Chronic Systolic Congestive Heart Failure Exacerbation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Diastolic Heart Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Episodic Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>NSTEMI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other, Acute Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Acute Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Altered Mental Status Due to Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Atypical Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Chest Pain Syndrome of Unknown Etiology</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Community Acquired RUL Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Difficulty Swallowing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Dyspnea on Extertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Intermittent Chest Discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Multi-organ Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Pain - Right Upper Chest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Shortness of Breath Due to Influenza A</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Urinary Retension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Gangrenous Changes to Bilateral Metatarsals</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Poor Healing Bilateral TMA Wounds Including Infection and Dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>RLE Abscess on Shin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Septic Schock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bleeding (other than access site)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Head Trauma S/P Substantial Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Degenerative Joint Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Left Patella Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Acute on Chronic Kidney Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Acute Renal Failure (CR 1.06)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Burn to Left Heel</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Ulcer Right Heel</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Access Site Complication</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Perforation, NHLBI Type I or II</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Vessel dissection, Grade A or B</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Unplanned Limb Amputation (Minor or Non-Target Limb)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>TIA Before Admission</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Unplanned, Nontarget Limb Intervention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Clinically Driven Target Lesion Revascularization</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Clinically Driven Target Vessel Revascularization</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Loss of distal collateral flow</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Pain, new onset or worsening from baseline</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Emboli requiring intervention to resolve acutely</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Vessel dissection, Grade C or greater</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Pseudoaneurysm defined as device related disruption of the arterial wall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Other, Abrasion/Cellutitis (R) UE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>BTK PAD RLE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Intervention Of Contralateral Leg</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Non Target Revascularization</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PAD-LSFA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Pseudoaneurysm at Non-Index Procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Reperfusion Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Right Leg Ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Stenosis Contralateral (Right) Leg</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Stenosis of Left Common Fem Artery Following Procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, New Onset or Worsening from Baseline</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Access Site Complication</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Following the earliest of (a)publication of results, (b)receipt of notice stating that Study has been terminated or (c)18 months after completion or termination, Institution/Investigator (IN) shall have right to publish information &amp; data collected or produced, provided that drafts are provided to Sponsor (SP) at least 60 days prior to the first submission. SP shall comment within 45 days. IN shall delay publication/presentation to enable SP to secure patent or other proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elizabeth De Spain</name_or_title>
      <organization>Avinger</organization>
      <phone>650.241.7900 ext 7967</phone>
      <email>edespain@avinger.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

